Resona Asset Management Co. Ltd. Takes Position in Quanterix Co. (NASDAQ:QTRX)

Resona Asset Management Co. Ltd. bought a new position in shares of Quanterix Co. (NASDAQ:QTRX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,057 shares of the company’s stock, valued at approximately $55,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Bank of New York Mellon Corp lifted its position in Quanterix by 1.8% during the fourth quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company’s stock worth $1,150,000 after acquiring an additional 1,963 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Quanterix by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 863,503 shares of the company’s stock worth $9,181,000 after purchasing an additional 4,836 shares during the period. American Century Companies Inc. lifted its holdings in Quanterix by 9.1% during the 4th quarter. American Century Companies Inc. now owns 71,992 shares of the company’s stock worth $765,000 after purchasing an additional 6,023 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Quanterix in the 4th quarter valued at $66,000. Finally, Janney Capital Management LLC grew its holdings in Quanterix by 40.9% in the 4th quarter. Janney Capital Management LLC now owns 33,192 shares of the company’s stock valued at $353,000 after buying an additional 9,639 shares in the last quarter. Institutional investors own 86.48% of the company’s stock.

Quanterix Price Performance

Quanterix stock opened at $5.20 on Friday. The stock’s fifty day moving average price is $7.09 and its two-hundred day moving average price is $10.01. The firm has a market cap of $201.64 million, a PE ratio of -4.91 and a beta of 1.35. Quanterix Co. has a one year low of $4.67 and a one year high of $19.71.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The company had revenue of $35.16 million during the quarter, compared to analyst estimates of $34.93 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. Sell-side analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Scotiabank reissued an “outperform” rating on shares of Quanterix in a report on Tuesday, March 25th. Canaccord Genuity Group dropped their price objective on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.